Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 77 articles:
HTML format

Single Articles

    October 2023
  1. PLEUNIS N, Pouwer AW, Oonk MHM, van Doorn HC, et al
    Incidence of inguinofemoral lymph node metastases at the first local recurrence of vulvar cancer: a Dutch nationwide study.
    Br J Cancer. 2023;129:956-964.
    PubMed     Abstract available

  2. BHAMIDIPATI D, Haro-Silerio JI, Yap TA, Ngoi N, et al
    PARP inhibitors: enhancing efficacy through rational combinations.
    Br J Cancer. 2023;129:904-916.
    PubMed     Abstract available

    August 2023
  3. CHOI JA, Kim H, Kwon H, Lee EH, et al
    Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
    Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02355.
    PubMed     Abstract available

  4. JOHNSON CE, Alberg AJ, Bandera EV, Peres LC, et al
    Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02385.
    PubMed     Abstract available

  5. THAVANESWARAN S, Kansara M, Lin F, Espinoza D, et al
    A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
    Br J Cancer. 2023;129:475-485.
    PubMed     Abstract available

    July 2023
  6. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    PubMed     Abstract available

  7. ZHANG Z, Zhang M, Zhou J, Wang D, et al
    Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy.
    Br J Cancer. 2023 Jul 4. doi: 10.1038/s41416-023-02347.
    PubMed     Abstract available

  8. KERRISON RS, Jones A, Peng J, Price G, et al
    Inequalities in cancer screening participation between adults with and without severe mental illness: results from a cross-sectional analysis of primary care data on English Screening Programmes.
    Br J Cancer. 2023;129:81-93.
    PubMed     Abstract available

    June 2023
  9. KAO WH, Kuo CF, Chang CC, Liu YC, et al
    Cancer survivorship and risk of pregnancy complications, adverse obstetric outcomes, and maternal morbidities in female adolescents and young adults: a nationwide population-based study from Taiwan.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02333.
    PubMed     Abstract available

  10. YANG Z, Wang XL, Bai R, Liu WY, et al
    Retraction Note: miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02328.

    May 2023
  11. PEREMIQUEL-TRILLAS P, Gomez D, Martinez JM, Fernandez-Gonzalez S, et al
    Cost-effectiveness analysis of molecular testing in minimally invasive samples to detect endometrial cancer in women with postmenopausal bleeding.
    Br J Cancer. 2023 May 10. doi: 10.1038/s41416-023-02291.
    PubMed     Abstract available

    April 2023
  12. QUINTELA M, James DW, Garcia J, Edwards K, et al
    In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02274.
    PubMed     Abstract available

  13. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening.
    Br J Cancer. 2023 Apr 26:1-8. doi: 10.1038/s41416-023-02277.
    PubMed     Abstract available

  14. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    PubMed     Abstract available

  15. KAMAL M, Lameiras S, Deloger M, Morel A, et al
    Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
    Br J Cancer. 2023 Apr 13. doi: 10.1038/s41416-023-02261.

  16. MARTIN AL, Colin-Leitzinger CM, Sinha SK, Chern JY, et al
    Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
    Br J Cancer. 2023 Apr 6. doi: 10.1038/s41416-023-02259.
    PubMed     Abstract available

    March 2023
  17. LONG X, Lu H, Cai MC, Zang J, et al
    APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
    Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02239.
    PubMed     Abstract available

  18. MITTELSTADT S, Kelemen O, Admard J, Gschwind A, et al
    Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse.
    Br J Cancer. 2023 Mar 27. doi: 10.1038/s41416-023-02233.
    PubMed     Abstract available

  19. GILHAM C, Sargent A, Crosbie EJ, Peto J, et al
    Long-term risks of invasive cervical cancer following HPV infection: follow-up of two screening cohorts in Manchester.
    Br J Cancer. 2023 Mar 23. doi: 10.1038/s41416-023-02227.
    PubMed     Abstract available

    February 2023
  20. WALKER TDJ, Faraahi ZF, Price MJ, Hawarden A, et al
    The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
    Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02168.
    PubMed     Abstract available

  21. NJOKU K, Pierce A, Geary B, Campbell AE, et al
    Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
    PubMed     Abstract available

  22. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02205.

  23. ASAMI Y, Kobayashi Kato M, Hiranuma K, Matsuda M, et al
    Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.
    Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02203.
    PubMed     Abstract available

  24. COLOMBO N, Gadducci A, Sehouli J, Rulli E, et al
    INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 m
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-022-02108.
    PubMed     Abstract available

  25. LEYDEN GM, Greenwood MP, Gaborieau V, Han Y, et al
    Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation.
    Br J Cancer. 2023;128:618-625.
    PubMed     Abstract available

    January 2023
  26. KRALJ J, Pernar Kovac M, Dabelic S, Polancec DS, et al
    Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02140.
    PubMed     Abstract available

  27. VERMIJ L, Jobsen JJ, Leon-Castillo A, Brinkhuis M, et al
    Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
    Br J Cancer. 2023 Jan 23. doi: 10.1038/s41416-023-02141.
    PubMed     Abstract available

  28. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
    Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
    PubMed     Abstract available

    December 2022
  29. SANDVEI MS, Pinborg A, Gissler M, Bergh C, et al
    Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)-a registry-based Nordic cohort study with follow-up from first pregnancy.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02097.
    PubMed     Abstract available

  30. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    PubMed     Abstract available

  31. COSTA S, Verberckmoes B, Castle PE, Arbyn M, et al
    Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.
    Br J Cancer. 2022 Dec 14. doi: 10.1038/s41416-022-02094.
    PubMed     Abstract available

  32. KRISTELEIT RS, Drew Y, Oza AM, Domchek SM, et al
    Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022.
    PubMed     Abstract available

  33. BERG HF, Engerud H, Myrvold M, Lien HE, et al
    Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02063.
    PubMed     Abstract available

  34. MURUMAGI A, Ungureanu D, Khan S, Arjama M, et al
    Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02067.
    PubMed     Abstract available

    November 2022
  35. BAX HJ, Chauhan J, Stavraka C, Santaolalla A, et al
    Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
    Br J Cancer. 2022 Nov 19. doi: 10.1038/s41416-022-02031.
    PubMed     Abstract available

  36. WEIR A, Kang EY, Meagher NS, Nelson GS, et al
    Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02014.
    PubMed     Abstract available

    September 2022
  37. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    PubMed     Abstract available

  38. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.

  39. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    PubMed     Abstract available

    August 2022
  40. AASBO G, Trope A, Nygard M, Christiansen IK, et al
    HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01954.
    PubMed     Abstract available

  41. GAHLAWAT AW, Witte T, Haarhuis L, Schott S, et al
    A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Br J Cancer. 2022 Aug 5. pii: 10.1038/s41416-022-01925.
    PubMed     Abstract available

    July 2022
  42. MUSACCHIO L, Califano D, Bartoletti M, Arenare L, et al
    Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01897.
    PubMed     Abstract available

  43. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    PubMed     Abstract available

    June 2022
  44. SASAMOTO N, Wang T, Townsend MK, Eliassen AH, et al
    Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
    Br J Cancer. 2022 Jun 27. pii: 10.1038/s41416-022-01901.
    PubMed     Abstract available

  45. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    PubMed     Abstract available

  46. KAMAT K, Krishnan V, Dorigo O
    Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
    Br J Cancer. 2022 Jun 24. pii: 10.1038/s41416-022-01887.
    PubMed     Abstract available

  47. HERBST J, Pantel K, Effenberger K, Wikman H, et al
    Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01868.
    PubMed     Abstract available

  48. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
    A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
    Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
    PubMed     Abstract available

  49. HOLLIS RL, Croy I, Churchman M, Bartos C, et al
    Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01874.
    PubMed     Abstract available

  50. KOTSOPOULOS J, Zamani N, Rosen B, McLaughlin JR, et al
    Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Br J Cancer. 2022 Jun 16. pii: 10.1038/s41416-022-01840.
    PubMed     Abstract available

  51. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
    Incidence trends for twelve cancers in younger adults-a rapid review.
    Br J Cancer. 2022;126:1374-1386.
    PubMed     Abstract available

    May 2022
  52. MENON U, Weller D, Falborg AZ, Jensen H, et al
    Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01844.
    PubMed     Abstract available

  53. CHEN T, Yu T, Zhuang S, Geng Y, et al
    Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01836.
    PubMed     Abstract available

  54. EL HELALI A, Plummer R, Jayson GC, Coyle VM, et al
    A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
    Br J Cancer. 2022 May 14. pii: 10.1038/s41416-022-01780.
    PubMed     Abstract available

    April 2022
  55. CREMONA M, Vandenberg CJ, Farrelly AM, Madden SF, et al
    BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    Br J Cancer. 2022 Apr 30. pii: 10.1038/s41416-022-01823.
    PubMed     Abstract available

  56. JI M, Jiang S, Zhao J, Wan X, et al
    Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
    Br J Cancer. 2022 Apr 22. pii: 10.1038/s41416-022-01809.
    PubMed     Abstract available

  57. KOIZUME S, Takahashi T, Nakamura Y, Yoshihara M, et al
    Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01808.
    PubMed     Abstract available

  58. SHAKFA N, Li D, Nersesian S, Wilson-Sanchez J, et al
    The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
    Br J Cancer. 2022 Apr 5. pii: 10.1038/s41416-022-01797.
    PubMed     Abstract available

  59. KONSTANTINOPOULOS PA, Cheng SC, Supko JG, Polak M, et al
    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Br J Cancer. 2022;126:1027-1036.
    PubMed     Abstract available

    March 2022
  60. YOU B, Van Wagensveld L, Tod M, Sonke GS, et al
    Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    Br J Cancer. 2022 Mar 31. pii: 10.1038/s41416-022-01732.
    PubMed     Abstract available

  61. REBOLJ M, Pesola F, Mathews C, Mesher D, et al
    The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01791.
    PubMed     Abstract available

  62. SEITZ S, Dreyer TF, Stange C, Steiger K, et al
    CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    Br J Cancer. 2022 Mar 21. pii: 10.1038/s41416-022-01763.
    PubMed     Abstract available

  63. MORGAN RD, Burghel GJ, Flaum N, Bulman M, et al
    BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Br J Cancer. 2022 Mar 8. pii: 10.1038/s41416-022-01773.
    PubMed     Abstract available

    February 2022
  64. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01717.
    PubMed     Abstract available

    January 2022
  65. YE S, Li Q, Wu Y, Jiang W, et al
    Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01705.
    PubMed     Abstract available

  66. MUKAMA T, Fortner RT, Katzke V, Hynes LC, et al
    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Br J Cancer. 2022 Jan 14. pii: 10.1038/s41416-021-01697.
    PubMed     Abstract available

  67. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    PubMed     Abstract available

    December 2021
  68. FOTOPOULOU C, Rockall A, Lu H, Lee P, et al
    Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01662.
    PubMed     Abstract available

    November 2021
  69. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available

  70. DICK S, Vink FJ, Heideman DAM, Lissenberg-Witte BI, et al
    Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
    Br J Cancer. 2021 Nov 6. pii: 10.1038/s41416-021-01614.
    PubMed     Abstract available

  71. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    PubMed     Abstract available

    October 2021
  72. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    PubMed     Abstract available

  73. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available

  74. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available

  75. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    PubMed     Abstract available

    September 2021
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    PubMed     Abstract available

    March 2021
  77. EINBOND LS, Zhou J, Wu HA, Mbazor E, et al
    A novel cancer preventative botanical mixture, TriCurin, inhibits viral transcripts and the growth of W12 cervical cells harbouring extrachromosomal or integrated HPV16 DNA.
    Br J Cancer. 2021;124:901-913.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.